JP2022516496A5 - - Google Patents
Info
- Publication number
- JP2022516496A5 JP2022516496A5 JP2021537987A JP2021537987A JP2022516496A5 JP 2022516496 A5 JP2022516496 A5 JP 2022516496A5 JP 2021537987 A JP2021537987 A JP 2021537987A JP 2021537987 A JP2021537987 A JP 2021537987A JP 2022516496 A5 JP2022516496 A5 JP 2022516496A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- linker
- chimeric receptor
- receptor polypeptide
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019071609 | 2019-01-14 | ||
| CNPCT/CN2019/071609 | 2019-01-14 | ||
| PCT/CN2020/071947 WO2020147708A1 (en) | 2019-01-14 | 2020-01-14 | Chimeric receptor polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516496A JP2022516496A (ja) | 2022-02-28 |
| JP2022516496A5 true JP2022516496A5 (enExample) | 2023-01-19 |
Family
ID=71614406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537987A Pending JP2022516496A (ja) | 2019-01-14 | 2020-01-14 | キメラ受容体ポリペプチド及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230192805A1 (enExample) |
| EP (1) | EP3911370A4 (enExample) |
| JP (1) | JP2022516496A (enExample) |
| KR (1) | KR20210116478A (enExample) |
| CN (1) | CN113164626A (enExample) |
| AU (1) | AU2020208110A1 (enExample) |
| CA (1) | CA3126422A1 (enExample) |
| SG (1) | SG11202106257WA (enExample) |
| WO (1) | WO2020147708A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2022228579A1 (en) * | 2021-04-30 | 2022-11-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting gpc3 and methods of use thereof |
| WO2023274382A1 (zh) * | 2021-06-30 | 2023-01-05 | 华夏英泰（北京）生物技术有限公司 | 一种多靶点合成t细胞受体抗原/抗体受体及其应用 |
| EP4370541A1 (en) * | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023164698A2 (en) * | 2022-02-27 | 2023-08-31 | Health Research, Inc. | FOLATE RECEPTOR ALPHA -TARGETING BI-SPECIFIC T CELL ENGAGERS (BiTEs) AND USES THEREOF |
| CN114560949B (zh) * | 2022-03-07 | 2023-09-26 | 中国人民解放军空军军医大学 | 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用 |
| CN114573712B (zh) * | 2022-03-07 | 2023-05-12 | 中国人民解放军空军军医大学 | 一种嵌合抗原受体、car-t细胞及其应用 |
| CN114560948B (zh) * | 2022-03-07 | 2023-05-23 | 中国人民解放军空军军医大学 | 一种嵌合抗原受体、car-t细胞及其应用 |
| US20260166144A1 (en) * | 2022-04-07 | 2026-06-18 | Carsgen Life Sciences Co., Ltd. | Chimeric polypeptide and use thereof |
| AR130387A1 (es) * | 2022-09-08 | 2024-12-04 | Hoffmann La Roche | Receptores de linfocitos t recombinantes |
| WO2024100136A1 (en) * | 2022-11-08 | 2024-05-16 | Gadeta B.V. | Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
| WO2024140710A1 (zh) * | 2022-12-26 | 2024-07-04 | 华夏英泰（北京）生物技术有限公司 | 一种特异性结合lilrb4的合成t细胞受体抗原受体及其应用 |
| WO2024140981A1 (zh) * | 2022-12-30 | 2024-07-04 | 上药生物治疗（香港）有限公司 | 细胞原位分泌抗体及其用途 |
| CN117074674B (zh) * | 2023-03-23 | 2024-01-23 | 武汉勖瑞生物科技有限责任公司 | 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法 |
| US20260234216A1 (en) * | 2023-03-30 | 2026-08-13 | Yale University | Universal antibody receptors, guar-t cells and therapeutic use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| CN105555804B (zh) * | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| US20170335009A1 (en) * | 2014-10-31 | 2017-11-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
| US10383929B2 (en) * | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| EP3770168A1 (en) * | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201604953D0 (en) * | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
| CN105777911B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
| US20190375815A1 (en) * | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| WO2018200582A1 (en) * | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
-
2020
- 2020-01-14 US US17/422,475 patent/US20230192805A1/en not_active Abandoned
- 2020-01-14 KR KR1020217022271A patent/KR20210116478A/ko not_active Withdrawn
- 2020-01-14 AU AU2020208110A patent/AU2020208110A1/en not_active Abandoned
- 2020-01-14 WO PCT/CN2020/071947 patent/WO2020147708A1/en not_active Ceased
- 2020-01-14 EP EP20741668.6A patent/EP3911370A4/en active Pending
- 2020-01-14 CN CN202080006993.7A patent/CN113164626A/zh active Pending
- 2020-01-14 JP JP2021537987A patent/JP2022516496A/ja active Pending
- 2020-01-14 SG SG11202106257WA patent/SG11202106257WA/en unknown
- 2020-01-14 CA CA3126422A patent/CA3126422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250059283A1 (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
| US20240294599A1 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
| EP4148125A1 (en) | Engineered immune cell for allotransplantation | |
| CN113321737A (zh) | 新型嵌合抗原受体及其用途 | |
| WO2021147928A1 (zh) | 包含嵌合抗原受体的免疫细胞及其用途 | |
| WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
| CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
| US20240009308A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| JP2024505955A (ja) | 新型キメラ抗原受容体及びその使用 | |
| CN115216449A (zh) | 工程化免疫细胞及其用途 | |
| US20250297259A1 (en) | Engineered immune cell with ciita gene knock-out and use thereof | |
| CN117004603A (zh) | 一种cd7基因被敲除的工程化免疫细胞及其用途 | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| CN117430712A (zh) | 靶向cxcr6的嵌合抗原受体及其用途 | |
| WO2026082164A1 (en) | A modified dual-targeting t cell receptor complex and its pharmaceutical application thereof | |
| WO2023083003A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023241141A1 (zh) | 靶向ccr8的嵌合抗原受体及其用途 | |
| CN115725504A (zh) | 工程化免疫细胞及其用途 | |
| CN115704010A (zh) | 工程化免疫细胞及其用途 | |
| HK40084045A (en) | Engineered immune cell for allotransplantation | |
| CA2974434C (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
| HK40110123A (en) | Engineered immune cell targeting bcma and use thereof | |
| WO2023071811A1 (zh) | 工程化免疫细胞及其用途 | |
| CN118995629A (zh) | 工程化细胞及其用途 |